←
Roberto Contieri728 posts
Roberto Contieri avatar✓

Roberto Contieri ✓

@RobertoContieri

Urologist @istitutotumori via @HumanitasMilano @MDAndersonNews @NKI_nl Member @EAU_YAUrotheli Member @IBCG_BladderCA

◷ Joined February 2012▧ 64 Photos and videos
Uromigos avatar
⟳ Roberto Contieri retweeted
Uromigos@Uromigos·Nov 2

The Uromigos World Cup is here! Countries are competing for the ultimate prize: the 🏆! First up, Team Netherlands 🇳🇱 #UromigosLive

2:34
Uromigos avatar
⟳ Roberto Contieri retweeted
Uromigos@Uromigos·Nov 3

🇮🇹 Gli Azzurri are coming for the Uromigos World Cup! ⚽🏆 From the Duomo di Milano to the latest in bladder preservation, Team Italy is bringing the Milan criteria for clinical complete response to the pitch. And they've got a message for the competition: We're coming for you! 👀 🎥 : @giannatempopatr & @CMercinelli | #UromigosLive

1:56
Società Italiana di Urologia avatar
⟳ Roberto Contieri retweeted
Società Italiana di Urologia@SIU_Italia·Oct 29

Premio Rising Star, destinato a tre giovani e promettenti urologi Under 33 che abbiano dimostrato caratteristiche qualitative di rilievo in ambito scientifico, afferenti alle seguenti macroaree: nord in memoria di Paolo Bianchi, centro in memoria di Giorgio Martino e sud in memoria di Davide Loizzo. Vincitore nord: Luca Afferi Affiliazione: Kantonsspital Aarau, Svizzera Vincitore nord: Luigi Nocera Affiliazione: ASST Spedali Civili, Brescia Vincitore centro: Antonio Grosso Affiliazione: Azienda Ospedaliero Universitaria Careggi, Firenze Vincitore sud: Roberto Contieri Affiliazione: IRCCS Istituto Nazionale Tumori — Fondazione “G. Pascale”, Napoli #Urologia #SIU26

Post attachmentPost attachmentPost attachment
OncoAlert avatar
⟳ Roberto Contieri retweeted
OncoAlert@OncoAlert·Jul 30

Three landmark studies. One network meta-analysis. Which perioperative strategy currently shows the strongest signal for improving survival in muscle-invasive bladder cancer? This analysis compares today's leading approaches and explores what the evidence can—and cannot—tell us. Article👉 buff.ly/sUECNO9 Comparative efficacy of perioperative systemic therapies for muscle-invasive bladder cancer: a network meta-analysis of randomized trials This network meta-analysis evaluated perioperative treatment strategies for muscle-invasive #BladderCancer using data from three randomised trials. Compared with gemcitabine–cisplatin, both enfortumab vedotin–pembrolizumab and gemcitabine–cisplatin plus durvalumab📈 improved overall survival, event-free survival, and pathological complete response, with enfortumab vedotin–pembrolizumab ranking highest across outcomes. Although based on indirect comparisons within a sparse network, these findings help contextualise emerging perioperative treatment options and inform clinical decision-making. @albisinnidoc
@andreamari08
@FraClaps
@RobertoContieri
@agallioli
@DavDandrea
@E_Laukhtina
@wojciechpiotrk1
@elijeandin
@Luca_Afferi
@f_delgiudice
@UroMoschini
@LAUrology_NL
@Anto_cigliola
@CMercinelli
@MatteoSantoniMD
@BenjaminPradere
@AndreaNecchi Pinging faculty @DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @AlbigesL @cdanicas @amerseburger @sonpavde @DrDanielHeng @declangmurphy @seanmmcbride @HHammersMD @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @scocmem @ravikanesvaran @AmandaNizamMD @drenriquegrande @BraunMDPhD @EfstathiouEleni @nataliagandur @crisbergerot

Post attachment
Ashish M. Kamat, MD, MBBS avatar
⟳ Roberto Contieri retweeted
Ashish M. Kamat, MD, MBBS@UroDocAsh·Jun 12

Congratulations to @LauraBukavinaMD @jaymsiva @drjkaouk and @ClevelandClinic team on largest external validation of the IBCG IR NMIBC substratification model 📊 2822 patients | 20 years | 3-year recurrence by subgroup: 🟢 IR-low: 12% 🟡 IR-intermediate: 38% 🔴 IR-high: 77% Progression followed the same stepwise pattern. Fine-Gray competing-risk models confirmed significance (p<0.001) - separation held on 12-month landmark analysis, ruling out early-event bias. Yet more evidence that trials enrolling IR NMIBC should stratify by IBCG subgroup at enrollment to be clinically meaningful. Conflating patients with 12% and 77% recurrence risk in the same trial arm is a fundamental problem. Full text: authors.elsevier.com/sd/arti… @IBCG_BladderCA

Post attachmentPost attachment
UroToday.com avatar
⟳ Roberto Contieri retweeted
UroToday.com@urotoday·Jun 2

A multi-center study examines maintenance schedules for intermediate-risk #NMIBC. @RobertoContieri @IstTumori joins @UroDocAsh @UTMDAnderson to discuss the results which include two-year recurrence-free survival of 55% with no maintenance versus 78% with any maintenance. Classification and regression tree analysis identified optimal cutoff at more than six monthly instillations. #WatchNow on UroToday > bit.ly/3OEHP5m

2:08
Max Kates avatar
⟳ Roberto Contieri retweeted
Max Kates@MaxKates·May 29

1) Approval based on marginal improvements in efficacy (without improvement to CSS/OS) 2) Toxicity that isn't G5 (death) doesn't seem to impact approval. 10-15% serious autoimmune AEs in NMIBC is deemed ok 3) little weight given to efficacy vs toxicity balance of a drug